Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
Read more -
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
Read more -
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
Read more -
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
Read more -
GSK begins shipping record number of its influenza vaccine doses for 2020-21 season for US market
GSK produces largest supply ever as CDC urges adults and high-risk individuals to be immunized against influenza during COVID-19 pandemic
Read more -
GSK and CureVac announce strategic mRNA technology collaboration
GSK and CureVac announce strategic mRNA technology collaboration
Read more -
GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma
press release
Read more -
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir
Read more -
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine.
Read more -
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices
Findings presented showed healthcare providers perceived implementation of the treatment as feasible and appropriate for people with HIV.
Read more -
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
Read more -
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
ViiV Healthcare will present over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), 6-10 July.
Read more -
GSK Consumer Healthcare selects Publicis Production and Tag to reinvent end-to-end marketing ecosystem
GSK announced that it has formed a global partnership with Publicis Production and Tag that will reinvent its marketing ecosystem.
Read more -
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease
Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD).
Read more -
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma
GSK announces FDA Advisory Committee meeting to review belantamab mafodotin
Read more -
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019
Read more -
GSK Science in the Summer™ Returns Virtually for Summer 2020 in Partnership with The Franklin Institute
GSK Science in the Summer™ returns this summer as an entirely virtual offering with a new theme: Be a Chemist!
Read more -
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
Read more -
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
Read more -
GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel
Voltaren Arthritis Pain Gel partners with Paula Abdul to launch prescription-strength NSAID gel for arthritis pain available OTC
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
